Pfizer Ibrance Breast Cancer Drug has managed to Successfully get the Preliminary Approval. Drugs for Breast Cancer Ibrance Pfizer moved its clinical trial in advanced stages due to problems where progress efficiency ceased. Pfizer, fortunately, managed to overcome the problem and everything is now back on track.
Mace Rothenberg, MD, senior vice president of Clinical Development and Medical Affairs and the chief medical officer for Pfizer Oncology said, “The results of this trial are especially important because they help us understand the potential of Ibrance to improve outcomes in patients with this difficult-to-treat cancer. We’re gratified to be able to stop the trial early and are engaging in discussions with health authorities regarding a regulatory path forward.”
After the drug got approval, PALOMA-1 study co-author Dennis Slamon, MD, PhD and professor of medicine and director of the Revlon/UCLA Women’s Cancer Research Program said, “With the FDA approval, this study represents a potential practice-changing result. I believe palbociclib will now become a standard treatment approach for postmenopausal women with ER+/HER2- metastatic breast cancer.”
When the drug was compared against Novartis Ag Femara, Ibrace performed far more effectively in terms of breast progression delay. Now after all this progress, Pfizer is now waiting on a regulatory board’s decision to moved forward on the new breast cancer drug.
The confirmation should encourage the drug-makers to accelerate the drug trials in order to further move on. Meanwhile Pfizer is still awaiting data from the PALOMA-2 trials. With this news Pfizer’s shares shot up to around one percent reaching $35.34 in afternoon trading at the New York Stock Exchange.